Insider Selling: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells 11,119 Shares of Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Donald Notman sold 11,119 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total value of $86,839.39. Following the transaction, the insider now directly owns 193,444 shares in the company, valued at $1,510,797.64. This trade represents a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Donald Notman also recently made the following trade(s):

• On Friday, January 31st, Donald Notman sold 6,301 shares of Ocular Therapeutix stock. The shares were sold at an average price of $7.84, for a total value of $49,399.84.

Ocular Therapeutix Trading Up 3.6 %

Shares of Ocular Therapeutix stock opened at $7.82 on Wednesday. The business has a 50 day moving average of $8.61 and a 200 day moving average of $9.02. Ocular Therapeutix, Inc. has a 52 week low of $4.06 and a 52 week high of $11.77. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01.

Institutional Investors Weigh In On Ocular Therapeutix

Several institutional investors and hedge funds have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Ocular Therapeutix by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 1,015 shares during the period. Essex Investment Management Co. LLC boosted its position in Ocular Therapeutix by 0.3% during the 3rd quarter. Essex Investment Management Co. LLC now owns 443,677 shares of the biopharmaceutical company’s stock valued at $3,860,000 after acquiring an additional 1,168 shares in the last quarter. HighVista Strategies LLC grew its holdings in shares of Ocular Therapeutix by 5.1% during the 3rd quarter. HighVista Strategies LLC now owns 65,027 shares of the biopharmaceutical company’s stock worth $566,000 after acquiring an additional 3,168 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Ocular Therapeutix by 11.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,336 shares of the biopharmaceutical company’s stock worth $285,000 after acquiring an additional 3,347 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of Ocular Therapeutix by 2.7% in the 4th quarter. Rhumbline Advisers now owns 213,601 shares of the biopharmaceutical company’s stock valued at $1,824,000 after purchasing an additional 5,682 shares during the period. 59.21% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

OCUL has been the subject of several recent research reports. Scotiabank assumed coverage on Ocular Therapeutix in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Ocular Therapeutix in a report on Tuesday, December 3rd. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.71.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.